Ellume was founded during the 2009 H1N1 pandemic by Dr Sean Parsons. Working as a physician in an emergency department, he faced a lack of fast, accurate diagnostic tests that were essential in reducing transmission and enabling early treatment.
Through its technical innovations, Ellume has developed, manufactured, and commercialized the next generation of rapid, highly accurate and affordable digital diagnostic products.
Despite advances in modern medicine, infectious diseases continue to pose a significant threat to humanity. Ellume was founded to address these problems through innovative approaches to diagnosis and treatment accessibility.
During the 2009 swine flu pandemic I was working as a physician in a busy emergency department. Scores of patients were presenting with symptoms of influenza. Laboratory tests took several days to return results and the small range of rapid influenza tests available lacked accuracy and reliability. Inappropriate prescribing of antivirals and antibiotics was unavoidable, as was non-prescribing for influenza infected patients. It was then that I realised there was a clear need for a faster, simpler and more accurate way to diagnose influenza and other infectious diseases.
The technology Ellume developed to meet this need consists of several layers of innovation. Investment in the core science has been significant and has resulted in multiple patent families. Around this core science we’ve wrapped simple, intuitive user interfaces with smart-device connectivity to create unique products.
Our technology has enabled us to create a digital diagnostic platform used across our entire product range. By integrating our high-performance diagnostic technology with smart devices and software, we are delivering additional value and are achieving better health outcomes. As we proceed, we’ll be looking to build on these strengths of digital, connected diagnostics and bring high-impact products to commercialization.
A culture of excellence
We are proud of the recognition we have received for our ongoing contributions to the development of innovative emerging technology for the benefit of humanity.